To the mooon
2021-10-06
Like
Boston Scientific Beefs Up Electrophysiology, Structural Heart Portfolio With $1.75B Baylis Deal
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
4
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":829536842,"tweetId":"829536842","gmtCreate":1633525678248,"gmtModify":1633525678777,"author":{"id":3576541645578836,"authorId":3576541645578836,"authorIdStr":"3576541645578836","name":"To the mooon","avatar":"https://static.tigerbbs.com/30f57ade5b12d911cd3934bfdf818a88","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":34,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like </p></body></html>","htmlText":"<html><head></head><body><p>Like </p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/829536842","repostId":1128708747,"repostType":4,"repost":{"id":"1128708747","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1633525260,"share":"https://www.laohu8.com/m/news/1128708747?lang=&edition=full","pubTime":"2021-10-06 21:01","market":"us","language":"en","title":"Boston Scientific Beefs Up Electrophysiology, Structural Heart Portfolio With $1.75B Baylis Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1128708747","media":"Benzinga","summary":"Boston Scientific Corporation has agreed to acquire Baylis Medical Company Inc for an upfront paymen","content":"<p><b>Boston Scientific Corporation</b> has agreed to acquire <b>Baylis Medical Company Inc</b> for an upfront payment of $1.75 billion.</p>\n<p>The acquisition will expand Boston Scientific's electrophysiology and structural heart product portfolios to include the radiofrequency (RF) NRG and VersaCross Transseptal Platforms and family of guidewires, sheaths, and dilators used to support left heart access.</p>\n<p>Baylis Medical Company is expected to generate net sales approaching $200 million in 2022.</p>\n<p>Baylis received FDA 510(k) clearance for the NRG platform in 2008, and the technology has since been used in more than one million procedures.</p>\n<p>The company received FDA 510(k) clearance for the VersaCross platform in 2020. The transaction will close in Q1 of 2022.</p>\n<p>The deal is expected to be approximately $0.01 accretive to adjusted EPS in 2022 and increasingly accretive after that.</p>\n<p>On a GAAP basis, the transaction is expected to be less accretive, or dilutive as the case may be, in 2022 and less dilutive or increasingly accretive after that, due to amortization expense and acquisition-related net charges.</p>\n<p><b>Price Action:</b> BSX stock traded 0.31% lower at $42.31 premarket on the last check Wednesday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Boston Scientific Beefs Up Electrophysiology, Structural Heart Portfolio With $1.75B Baylis Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBoston Scientific Beefs Up Electrophysiology, Structural Heart Portfolio With $1.75B Baylis Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-10-06 21:01</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Boston Scientific Corporation</b> has agreed to acquire <b>Baylis Medical Company Inc</b> for an upfront payment of $1.75 billion.</p>\n<p>The acquisition will expand Boston Scientific's electrophysiology and structural heart product portfolios to include the radiofrequency (RF) NRG and VersaCross Transseptal Platforms and family of guidewires, sheaths, and dilators used to support left heart access.</p>\n<p>Baylis Medical Company is expected to generate net sales approaching $200 million in 2022.</p>\n<p>Baylis received FDA 510(k) clearance for the NRG platform in 2008, and the technology has since been used in more than one million procedures.</p>\n<p>The company received FDA 510(k) clearance for the VersaCross platform in 2020. The transaction will close in Q1 of 2022.</p>\n<p>The deal is expected to be approximately $0.01 accretive to adjusted EPS in 2022 and increasingly accretive after that.</p>\n<p>On a GAAP basis, the transaction is expected to be less accretive, or dilutive as the case may be, in 2022 and less dilutive or increasingly accretive after that, due to amortization expense and acquisition-related net charges.</p>\n<p><b>Price Action:</b> BSX stock traded 0.31% lower at $42.31 premarket on the last check Wednesday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BSX":"波士顿科学"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128708747","content_text":"Boston Scientific Corporation has agreed to acquire Baylis Medical Company Inc for an upfront payment of $1.75 billion.\nThe acquisition will expand Boston Scientific's electrophysiology and structural heart product portfolios to include the radiofrequency (RF) NRG and VersaCross Transseptal Platforms and family of guidewires, sheaths, and dilators used to support left heart access.\nBaylis Medical Company is expected to generate net sales approaching $200 million in 2022.\nBaylis received FDA 510(k) clearance for the NRG platform in 2008, and the technology has since been used in more than one million procedures.\nThe company received FDA 510(k) clearance for the VersaCross platform in 2020. The transaction will close in Q1 of 2022.\nThe deal is expected to be approximately $0.01 accretive to adjusted EPS in 2022 and increasingly accretive after that.\nOn a GAAP basis, the transaction is expected to be less accretive, or dilutive as the case may be, in 2022 and less dilutive or increasingly accretive after that, due to amortization expense and acquisition-related net charges.\nPrice Action: BSX stock traded 0.31% lower at $42.31 premarket on the last check Wednesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":94,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/829536842"}
精彩评论